GLENN JOHN 4
4 · IRADIMED CORP · Filed Dec 12, 2025
Insider Transaction Report
Form 4
IRADIMED CORPIRMD
GLENN JOHN
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-12-11$97.26/sh−14,468$1,407,158→ 7,894 total - Sale
Common Stock
2025-12-11$98.09/sh−532$52,184→ 7,362 total - Exercise/Conversion
Common Stock
2025-12-11+1,812→ 9,174 total - Tax Payment
Common Stock
2025-12-11$97.38/sh−714$69,529→ 8,460 total - Exercise/Conversion
Restricted Stock Units
2025-12-11−1,812→ 3,624 total→ Common Stock (1,812 underlying)
Footnotes (3)
- [F1]This transaction was executed in multiple trades at prices ranging from $97.00 to $97.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]Restricted stock units convert into common stock on a one-for-one basis.
- [F3]The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.